{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T11:00:19Z","timestamp":1785495619658,"version":"3.56.0"},"reference-count":104,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-12445-y","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T10:28:36Z","timestamp":1785493716000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Carbohydrates metabolic reprogramming and tumor microenvironment in pancreatic cancer: targeting pathways"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-9693-5058","authenticated-orcid":false,"given":"Habiba","family":"Osama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8008-9966","authenticated-orcid":false,"given":"Ekram","family":"Saleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,31]]},"reference":[{"issue":"1","key":"12445_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","volume":"69","author":"RL Siegel","year":"2019","unstructured":"Siegel RL, Miller KD, Jemal A (2019) Cancer statistics, 2019. CA Cancer J Clin 69(1):7\u201334. https:\/\/doi.org\/10.3322\/caac.21551","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"12445_CR2","doi-asserted-by":"publisher","DOI":"10.1080\/08941939.2022.2129884","volume":"36","author":"HM Kolbeinsson","year":"2023","unstructured":"Kolbeinsson HM, Chandana S, Wright GP, Chung M (2023) Pancreatic cancer: a review of current treatment and novel therapies. J Investig Surg 36(1):2129884. https:\/\/doi.org\/10.1080\/08941939.2022.2129884","journal-title":"J Investig Surg"},{"issue":"7","key":"12445_CR3","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1093\/annonc\/mdr541","volume":"23","author":"C Bosetti","year":"2012","unstructured":"Bosetti C, Lucenteforte E, Silverman DT, Petersen G, Bracci PM, Ji BT et al (2012) Cigarette smoking and pancreatic cancer: an analysis from the international pancreatic cancer case-control consortium (Panc4). Ann Oncol. 23(7):1880\u20138. https:\/\/doi.org\/10.1093\/annonc\/mdr541","journal-title":"Ann Oncol."},{"issue":"18","key":"12445_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20184504","volume":"20","author":"S Zeng","year":"2019","unstructured":"Zeng S, P\u00f6ttler M, Lan B, Gr\u00fctzmann R, Pilarsky C, Yang H (2019) Chemoresistance in pancreatic cancer. Int J Mol Sci 20(18):4504. https:\/\/doi.org\/10.3390\/ijms20184504","journal-title":"Int J Mol Sci"},{"issue":"7","key":"12445_CR5","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41575-021-00457-x","volume":"18","author":"AP Klein","year":"2021","unstructured":"Klein AP (2021) Pancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors. Nat Rev Gastroenterol Hepatol 18(7):493\u2013502. https:\/\/doi.org\/10.1038\/s41575-021-00457-x","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"8","key":"12445_CR6","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-023-04855-z","volume":"80","author":"AC Lilly","year":"2023","unstructured":"Lilly AC, Astsaturov I, Golemis EA (2023) Intrapancreatic fat, pancreatitis, and pancreatic cancer. Cell Mol Life Sci 80(8):206. https:\/\/doi.org\/10.1007\/s00018-023-04855-z","journal-title":"Cell Mol Life Sci"},{"key":"12445_CR7","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jbior.2017.11.007","volume":"68","author":"A Adamska","year":"2018","unstructured":"Adamska A, Elaskalani O, Emmanouilidi A, Kim M, Abdol Razak NB, Metharom P et al (2018) Molecular and cellular mechanisms of chemoresistance in pancreatic cancer. Adv Biol Regul 68:77\u201387. https:\/\/doi.org\/10.1016\/j.jbior.2017.11.007","journal-title":"Adv Biol Regul"},{"issue":"6487","key":"12445_CR8","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaw5473","volume":"368","author":"B Faubert","year":"2020","unstructured":"Faubert B, Solmonson A, DeBerardinis RJ (2020) Metabolic reprogramming and cancer progression. Science 368(6487):eaaw5473. https:\/\/doi.org\/10.1126\/science.aaw5473","journal-title":"Science"},{"issue":"4","key":"12445_CR9","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1097\/CM9.0000000000002758","volume":"137","author":"J Zhang","year":"2024","unstructured":"Zhang J, Wang Y, Wang L, You L, Zhang T (2024) Pancreatic ductal adenocarcinoma chemoresistance: from metabolism reprogramming to novel treatment. Chin Med J (Engl) 137(4):408\u2013420. https:\/\/doi.org\/10.1097\/CM9.0000000000002758","journal-title":"Chin Med J (Engl)"},{"key":"12445_CR10","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.redox.2017.04.018","volume":"12","author":"B Kalyanaraman","year":"2017","unstructured":"Kalyanaraman B (2017) Teaching the basics of cancer metabolism: developing antitumor strategies by exploiting the differences between normal and cancer cell metabolism. Redox Biol 12:833\u2013842. https:\/\/doi.org\/10.1016\/j.redox.2017.04.018","journal-title":"Redox Biol"},{"issue":"5","key":"12445_CR11","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nrc3038","volume":"11","author":"WH Koppenol","year":"2011","unstructured":"Koppenol WH, Bounds PL, Dang CV (2011) Otto Warburg\u2019s contributions to current concepts of cancer metabolism. Nat Rev Cancer 11(5):325\u201337. https:\/\/doi.org\/10.1038\/nrc3038","journal-title":"Nat Rev Cancer"},{"issue":"16","key":"12445_CR12","doi-asserted-by":"publisher","first-page":"2926","DOI":"10.1111\/febs.14577","volume":"285","author":"PB Ancey","year":"2018","unstructured":"Ancey PB, Contat C, Meylan E (2018) Glucose transporters in cancer - from tumor cells to the tumor microenvironment. FEBS J 285(16):2926\u20132943. https:\/\/doi.org\/10.1111\/febs.14577","journal-title":"FEBS J"},{"issue":"9","key":"12445_CR13","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.22034\/APJCP.2018.19.9.2377","volume":"19","author":"C Marbaniang","year":"2018","unstructured":"Marbaniang C, Kma L (2018) Dysregulation of glucose metabolism by oncogenes and tumor suppressors in cancer cells. Asian Pac J Cancer Prev 19(9):2377\u20132390. https:\/\/doi.org\/10.22034\/APJCP.2018.19.9.2377","journal-title":"Asian Pac J Cancer Prev"},{"issue":"10","key":"12445_CR14","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.trecan.2017.08.006","volume":"3","author":"KM Haigis","year":"2017","unstructured":"Haigis KM (2017) KRAS alleles: the devil is in the detail. Trends Cancer 3(10):686\u2013697. https:\/\/doi.org\/10.1016\/j.trecan.2017.08.006","journal-title":"Trends Cancer"},{"issue":"1","key":"12445_CR15","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1053\/j.seminoncol.2021.02.003","volume":"48","author":"J Luo","year":"2021","unstructured":"Luo J (2021) KRAS mutation in pancreatic cancer. Semin Oncol 48(1):10\u201318. https:\/\/doi.org\/10.1053\/j.seminoncol.2021.02.003","journal-title":"Semin Oncol"},{"key":"12445_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1586959","volume":"16","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Li W, Niu J, Fan Z, Li X, Zhang H (2025) Reprogramming of glucose metabolism in pancreatic cancer: mechanisms, implications, and therapeutic perspectives. Front Immunol 16:1586959. https:\/\/doi.org\/10.3389\/fimmu.2025.1586959","journal-title":"Front Immunol"},{"issue":"9","key":"12445_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-05259-w","volume":"13","author":"YH Liu","year":"2022","unstructured":"Liu YH, Hu CM, Hsu YS, Lee WH (2022) Interplays of glucose metabolism and KRAS mutation in pancreatic ductal adenocarcinoma. Cell Death Dis 13(9):817. https:\/\/doi.org\/10.1038\/s41419-022-05259-w","journal-title":"Cell Death Dis"},{"key":"12445_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2023.108566","author":"E Di Giorgio","year":"2023","unstructured":"Di Giorgio E, Choudhary H, Ferino A, Cortolezzis Y, Dalla E, D\u2019Este F et al (2023) Suppression of the KRAS-NRF2 axis shifts arginine into the phosphocreatine energy system in pancreatic cancer cells. iScience. https:\/\/doi.org\/10.1016\/j.isci.2023.108566","journal-title":"iScience"},{"issue":"624","key":"12445_CR19","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aay6013","volume":"13","author":"CA Stalnecker","year":"2020","unstructured":"Stalnecker CA, Der CJ (2020) RAS, wanted dead or alive: advances in targeting RAS mutant cancers. Sci Signal 13(624):eaay6013. https:\/\/doi.org\/10.1126\/scisignal.aay6013","journal-title":"Sci Signal"},{"issue":"7","key":"12445_CR20","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.trecan.2021.01.008","volume":"7","author":"S Venkat","year":"2021","unstructured":"Venkat S, Alahmari AA, Feigin ME (2021) Drivers of gene expression dysregulation in pancreatic cancer. Trends Cancer 7(7):594\u2013605. https:\/\/doi.org\/10.1016\/j.trecan.2021.01.008","journal-title":"Trends Cancer"},{"issue":"1","key":"12445_CR21","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1053\/j.gastro.2018.09.022","volume":"156","author":"V Bernard","year":"2019","unstructured":"Bernard V, Kim DU, San Lucas FA, Castillo J, Allenson K, Mulu FC et al (2019) Circulating nucleic acids are associated with outcomes of patients with pancreatic cancer. Gastroenterology 156(1):108-118.e4. https:\/\/doi.org\/10.1053\/j.gastro.2018.09.022","journal-title":"Gastroenterology"},{"issue":"38","key":"12445_CR22","doi-asserted-by":"publisher","first-page":"10202","DOI":"10.1073\/pnas.1704961114","volume":"114","author":"JD Cohen","year":"2017","unstructured":"Cohen JD, Javed AA, Thoburn C, Wong F, Tie J, Gibbs P et al (2017) Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers. Proc Natl Acad Sci U S A 114(38):10202\u201310207. https:\/\/doi.org\/10.1073\/pnas.1704961114","journal-title":"Proc Natl Acad Sci U S A"},{"key":"12445_CR23","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.canlet.2020.07.041","volume":"492","author":"VM Shah","year":"2020","unstructured":"Shah VM, Sheppard BC, Sears RC, Alani AW (2020) Hypoxia: friend or foe for drug delivery in pancreatic cancer. Cancer Lett 492:63\u201370. https:\/\/doi.org\/10.1016\/j.canlet.2020.07.041","journal-title":"Cancer Lett"},{"issue":"24","key":"12445_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14246054","volume":"14","author":"BP Bui","year":"2022","unstructured":"Bui BP, Nguyen PL, Lee K, Cho J (2022) Hypoxia-inducible factor-1: a novel therapeutic target for the management of cancer, drug resistance, and cancer-related pain. Cancers (Basel) 14(24):6054. https:\/\/doi.org\/10.3390\/cancers14246054","journal-title":"Cancers (Basel)"},{"key":"12445_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103756","volume":"75","author":"V Llombart","year":"2022","unstructured":"Llombart V, Mansour MR (2022) Therapeutic targeting of \u201cundruggable\u201d MYC. EBioMedicine 75:103756. https:\/\/doi.org\/10.1016\/j.ebiom.2021.103756","journal-title":"EBioMedicine"},{"key":"12445_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-018-0008-7","volume":"3","author":"H Chen","year":"2018","unstructured":"Chen H, Liu H, Qing G (2018) Targeting oncogenic Myc as a strategy for cancer treatment. Signal Transduct Target Ther 3:5. https:\/\/doi.org\/10.1038\/s41392-018-0008-7","journal-title":"Signal Transduct Target Ther"},{"key":"12445_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00495","volume":"11","author":"X Liu","year":"2020","unstructured":"Liu X, Zhou Y, Peng J, Xie B, Shou Q, Wang J (2020) Silencing c-Myc enhances the antitumor activity of bufalin by suppressing the HIF-1\u03b1\/SDF-1\/CXCR4 pathway in pancreatic cancer cells. Front Pharmacol 11:495. https:\/\/doi.org\/10.3389\/fphar.2020.00495","journal-title":"Front Pharmacol"},{"issue":"Pt 2","key":"12445_CR28","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.semcancer.2022.09.001","volume":"86","author":"A Comandatore","year":"2022","unstructured":"Comandatore A, Franczak M, Smolenski RT, Morelli L, Peters GJ, Giovannetti E (2022) Lactate dehydrogenase and its clinical significance in pancreatic and thoracic cancers. Semin Cancer Biol 86(Pt 2):93\u2013100. https:\/\/doi.org\/10.1016\/j.semcancer.2022.09.001","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"12445_CR29","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1080\/15384047.2021.2017223","volume":"23","author":"M Ala","year":"2022","unstructured":"Ala M (2022) Target c-Myc to treat pancreatic cancer. Cancer Biol Ther 23(1):34\u201350. https:\/\/doi.org\/10.1080\/15384047.2021.2017223","journal-title":"Cancer Biol Ther"},{"issue":"16","key":"12445_CR30","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1002\/ejoc.201901353","volume":"2020","author":"ES Reckzeh","year":"2020","unstructured":"Reckzeh ES, Waldmann H (2020) Development of glucose transporter (GLUT) inhibitors. Eur J Org Chem 2020(16):2321\u20132329. https:\/\/doi.org\/10.1002\/ejoc.201901353","journal-title":"Eur J Org Chem"},{"issue":"2","key":"12445_CR31","doi-asserted-by":"publisher","first-page":"E141","DOI":"10.1152\/ajpendo.00712.2009","volume":"298","author":"B Thorens","year":"2010","unstructured":"Thorens B, Mueckler M (2010) Glucose transporters in the 21st century. Am J Physiol Endocrinol Metab 298(2):E141-5. https:\/\/doi.org\/10.1152\/ajpendo.00712.2009","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"12445_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.118603","volume":"264","author":"M Ghanavat","year":"2021","unstructured":"Ghanavat M, Shahrouzian M, Deris Zayeri Z, Banihashemi S, Kazemi SM, Saki N (2021) Digging deeper through glucose metabolism and its regulators in cancer and metastasis. Life Sci 264:118603. https:\/\/doi.org\/10.1016\/j.lfs.2020.118603","journal-title":"Life Sci"},{"issue":"9","key":"12445_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-05213-w","volume":"13","author":"K Cai","year":"2022","unstructured":"Cai K, Chen S, Zhu C, Li L, Yu C, He Z et al (2022) FOXD1 facilitates pancreatic cancer cell proliferation, invasion, and metastasis by regulating GLUT1-mediated aerobic glycolysis. Cell Death Dis 13(9):765. https:\/\/doi.org\/10.1038\/s41419-022-05213-w","journal-title":"Cell Death Dis"},{"issue":"2","key":"12445_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2020.188457","volume":"1874","author":"K Tilekar","year":"2020","unstructured":"Tilekar K, Upadhyay N, Iancu CV, Pokrovsky V, Choe JY, Ramaa CS (2020) Power of two: combination of therapeutic approaches involving glucose transporter (GLUT) inhibitors to combat cancer. Biochim Biophys Acta Rev Cancer 1874(2):188457. https:\/\/doi.org\/10.1016\/j.bbcan.2020.188457","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"16","key":"12445_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13164184","volume":"13","author":"M Pliszka","year":"2021","unstructured":"Pliszka M, Szablewski L (2021) Glucose transporters as a target for anticancer therapy. Cancers (Basel) 13(16):4184. https:\/\/doi.org\/10.3390\/cancers13164184","journal-title":"Cancers (Basel)"},{"key":"12445_CR36","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.molmet.2019.07.006","volume":"33","author":"VL Payen","year":"2020","unstructured":"Payen VL, Mina E, Van H\u00e9e VF, Porporato PE, Sonveaux P (2020) Monocarboxylate transporters in cancer. Mol Metab 33:48\u201366. https:\/\/doi.org\/10.1016\/j.molmet.2019.07.006","journal-title":"Mol Metab"},{"issue":"6","key":"12445_CR37","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24065141","volume":"24","author":"A Silva","year":"2023","unstructured":"Silva A, Cerqueira MC, Rosa B, Sobral C, Pinto-Ribeiro F, Costa MF et al (2023) Prognostic value of monocarboxylate transporter 1 overexpression in cancer: a systematic review. Int J Mol Sci 24(6):5141. https:\/\/doi.org\/10.3390\/ijms24065141","journal-title":"Int J Mol Sci"},{"issue":"7","key":"12445_CR38","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1097\/MPA.0000000000000571","volume":"45","author":"SC Kong","year":"2016","unstructured":"Kong SC, N\u00f8hr-Nielsen A, Zeeberg K, Reshkin SJ, Hoffmann EK, Novak I et al (2016) Monocarboxylate transporters MCT1 and MCT4 regulate migration and invasion of pancreatic ductal adenocarcinoma cells. Pancreas 45(7):1036\u201347. https:\/\/doi.org\/10.1097\/MPA.0000000000000571","journal-title":"Pancreas"},{"key":"12445_CR39","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/978-3-030-34025-4_3","volume":"1219","author":"A Pereira-Nunes","year":"2020","unstructured":"Pereira-Nunes A, Afonso J, Granja S, Baltazar F (2020) Lactate and lactate transporters as key players in the maintenance of the warburg effect. Adv Exp Med Biol. 1219:51\u201374. https:\/\/doi.org\/10.1007\/978-3-030-34025-4_3","journal-title":"Adv Exp Med Biol."},{"issue":"5","key":"12445_CR40","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.cmet.2016.08.011","volume":"24","author":"A Brand","year":"2016","unstructured":"Brand A, Singer K, Koehl GE, Kolitzus M, Schoenhammer G, Thiel A et al (2016) LDHA-associated lactic acid production blunts tumor immunosurveillance by T and NK cells. Cell Metab 24(5):657\u2013671. https:\/\/doi.org\/10.1016\/j.cmet.2016.08.011","journal-title":"Cell Metab"},{"key":"12445_CR41","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.1069555","volume":"10","author":"Q Duan","year":"2022","unstructured":"Duan Q, Zhang S, Wang Y, Lu D, Sun Y, Wu Y (2022) Proton-coupled monocarboxylate transporters in cancer: from metabolic crosstalk, immunosuppression and anti-apoptosis to clinical applications. Front Cell Dev Biol 10:1069555. https:\/\/doi.org\/10.3389\/fcell.2022.1069555","journal-title":"Front Cell Dev Biol"},{"issue":"6","key":"12445_CR42","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1007\/s13402-021-00643-8","volume":"44","author":"SH Lee","year":"2021","unstructured":"Lee SH, Hwang HK, Lee WJ, Kang CM (2021) MCT4 as a potential therapeutic target to augment gemcitabine chemosensitivity in resected pancreatic cancer. Cell Oncol (Dordr) 44(6):1363\u20131371. https:\/\/doi.org\/10.1007\/s13402-021-00643-8","journal-title":"Cell Oncol (Dordr)"},{"issue":"9","key":"12445_CR43","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22094716","volume":"22","author":"F Ciscato","year":"2021","unstructured":"Ciscato F, Ferrone L, Masgras I, Laquatra C, Rasola A (2021) Hexokinase 2 in cancer: a prima donna playing multiple characters. Int J Mol Sci 22(9):4716. https:\/\/doi.org\/10.3390\/ijms22094716","journal-title":"Int J Mol Sci"},{"issue":"1","key":"12445_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellin.2023.100077","volume":"2","author":"D Guo","year":"2023","unstructured":"Guo D, Meng Y, Jiang X, Lu Z (2023) Hexokinases in cancer and other pathologies. Cell Insight 2(1):100077. https:\/\/doi.org\/10.1016\/j.cellin.2023.100077","journal-title":"Cell Insight"},{"key":"12445_CR45","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.1108776","volume":"13","author":"C Liu","year":"2023","unstructured":"Liu C, Li C, Liu Y (2023) The role of metabolic reprogramming in pancreatic cancer chemoresistance. Front Pharmacol 13:1108776. https:\/\/doi.org\/10.3389\/fphar.2022.1108776","journal-title":"Front Pharmacol"},{"key":"12445_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2020.114213","volume":"182","author":"C Laussel","year":"2020","unstructured":"Laussel C, L\u00e9on S (2020) Cellular toxicity of the metabolic inhibitor 2-deoxyglucose and associated resistance mechanisms. Biochem Pharmacol 182:114213. https:\/\/doi.org\/10.1016\/j.bcp.2020.114213","journal-title":"Biochem Pharmacol"},{"issue":"34","key":"12445_CR47","doi-asserted-by":"publisher","first-page":"56081","DOI":"10.18632\/oncotarget.9760","volume":"8","author":"M Anderson","year":"2016","unstructured":"Anderson M, Marayati R, Moffitt R, Yeh JJ (2016) Hexokinase 2 promotes tumor growth and metastasis by regulating lactate production in pancreatic cancer. Oncotarget 8(34):56081\u201356094. https:\/\/doi.org\/10.18632\/oncotarget.9760","journal-title":"Oncotarget"},{"issue":"3","key":"12445_CR48","doi-asserted-by":"publisher","DOI":"10.3390\/metabo13030345","volume":"13","author":"MK Ediriweera","year":"2023","unstructured":"Ediriweera MK, Jayasena S (2023) The role of reprogrammed glucose metabolism in cancer. Metabolites 13(3):345. https:\/\/doi.org\/10.3390\/metabo13030345","journal-title":"Metabolites"},{"key":"12445_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/s40170-020-0210-2","volume":"8","author":"DA Richardson","year":"2020","unstructured":"Richardson DA, Sritangos P, James AD, Sultan A, Bruce JIE (2020) Metabolic regulation of calcium pumps in pancreatic cancer: role of phosphofructokinase-fructose-bisphosphatase-3 (PFKFB3). Cancer Metab 8:2. https:\/\/doi.org\/10.1186\/s40170-020-0210-2","journal-title":"Cancer Metab"},{"issue":"4","key":"12445_CR50","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13040909","volume":"13","author":"K Kotowski","year":"2021","unstructured":"Kotowski K, Rosik J, Machaj F, Supplitt S, Wiczew D, Jab\u0142o\u0144ska K et al (2021) Role of PFKFB3 and PFKFB4 in cancer: genetic basis, impact on disease development\/progression, and potential as therapeutic targets. Cancers (Basel) 13(4):909. https:\/\/doi.org\/10.3390\/cancers13040909","journal-title":"Cancers (Basel)"},{"issue":"1-2","key":"12445_CR51","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s11010-020-03751-5","volume":"470","author":"SC Ozcan","year":"2020","unstructured":"Ozcan SC, Sarioglu A, Altunok TH, Akkoc A, Guzel S, Guler S et al (2020) PFKFB2 regulates glycolysis and proliferation in pancreatic cancer cells. Mol Cell Biochem 470(1\u20132):115\u2013129. https:\/\/doi.org\/10.1007\/s11010-020-03751-5","journal-title":"Mol Cell Biochem"},{"issue":"6","key":"12445_CR52","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.tibs.2018.12.007","volume":"44","author":"P Icard","year":"2019","unstructured":"Icard P, Fournel L, Wu Z, Alifano M, Lincet H (2019) Interconnection between metabolism and cell cycle in cancer. Trends Biochem Sci 44(6):490\u2013501. https:\/\/doi.org\/10.1016\/j.tibs.2018.12.007","journal-title":"Trends Biochem Sci"},{"key":"12445_CR53","doi-asserted-by":"publisher","DOI":"10.1186\/s13578-019-0317-8","volume":"9","author":"Z Zhang","year":"2019","unstructured":"Zhang Z, Deng X, Liu Y, Liu Y, Sun L, Chen F (2019) PKM2, function and expression and regulation. Cell Biosci 9:52. https:\/\/doi.org\/10.1186\/s13578-019-0317-8","journal-title":"Cell Biosci"},{"issue":"1","key":"12445_CR54","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.yexcr.2015.05.017","volume":"336","author":"DJ Kim","year":"2015","unstructured":"Kim DJ, Park YS, Kang MG, You YM, Jung Y, Koo H, Kim JA, aI. (2015) Pyruvate kinase isoenzyme M2 is a therapeutic target of gemcitabine-resistant pancreatic cancer cells. Exp Cell Res. 336(1):119\u201329. https:\/\/doi.org\/10.1016\/j.yexcr.2015.05.017","journal-title":"Exp Cell Res."},{"issue":"16","key":"12445_CR55","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1038\/onc.2015.270","volume":"35","author":"S Calabretta","year":"2016","unstructured":"Calabretta S, Bielli P, Passacantilli I, Pilozzi E, Fendrich V, Capurso G et al (2016) Modulation of PKM alternative splicing by PTBP1 promotes gemcitabine resistance in pancreatic cancer cells. Oncogene 35(16):2031\u20139. https:\/\/doi.org\/10.1038\/onc.2015.270","journal-title":"Oncogene"},{"issue":"6","key":"12445_CR56","doi-asserted-by":"publisher","first-page":"750","DOI":"10.3390\/cancers12040932","volume":"11","author":"D Mishra","year":"2019","unstructured":"Mishra D, Banerjee D (2019) Lactate Dehydrogenases as Metabolic Links between Tumor and Stroma in the Tumor Microenvironment. Cancers (Basel). 11(6):750. https:\/\/doi.org\/10.3390\/cancers12040932","journal-title":"Cancers (Basel)."},{"issue":"2","key":"12445_CR57","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.ccell.2022.01.001","volume":"40","author":"S Kumagai","year":"2022","unstructured":"Kumagai S, Koyama S, Itahashi K, Tanegashima T, Lin YT, Togashi Y et al (2022) Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments. Cancer Cell 40(2):201-218.e9. https:\/\/doi.org\/10.1016\/j.ccell.2022.01.001","journal-title":"Cancer Cell"},{"key":"12445_CR58","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.canlet.2018.09.013","volume":"438","author":"YW Kang","year":"2018","unstructured":"Kang YW, Lee JE, Jung KH, Son MK, Shin SM, Kim SJ et al (2018) KRAS targeting antibody synergizes anti-cancer activity of gemcitabine against pancreatic cancer. Cancer Lett 438:174\u2013186. https:\/\/doi.org\/10.1016\/j.canlet.2018.09.013","journal-title":"Cancer Lett"},{"key":"12445_CR59","doi-asserted-by":"publisher","DOI":"10.3389\/fchem.2020.00829","volume":"8","author":"M Ashrafizadeh","year":"2020","unstructured":"Ashrafizadeh M, Bakhoda MR, Bahmanpour Z, Ilkhani K, Zarrabi A, Makvandi P et al (2020) Apigenin as tumor suppressor in cancers: biotherapeutic activity, nanodelivery, and mechanisms with emphasis on pancreatic cancer. Front Chem 8:829. https:\/\/doi.org\/10.3389\/fchem.2020.00829","journal-title":"Front Chem"},{"key":"12445_CR60","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.canlet.2017.10.041","volume":"413","author":"J Maduni\u0107","year":"2018","unstructured":"Maduni\u0107 J, Maduni\u0107 IV, Gajski G, Popi\u0107 J, Garaj-Vrhovac V (2018) Apigenin: a dietary flavonoid with diverse anticancer properties. Cancer Lett 413:11\u201322. https:\/\/doi.org\/10.1016\/j.canlet.2017.10.041","journal-title":"Cancer Lett"},{"issue":"18","key":"12445_CR61","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27186051","volume":"27","author":"AH Rahmani","year":"2022","unstructured":"Rahmani AH, Alsahli MA, Almatroudi A, Almogbel MA, Khan AA, Anwar S et al (2022) The potential role of apigenin in cancer prevention and treatment. Molecules 27(18):6051. https:\/\/doi.org\/10.3390\/molecules27186051","journal-title":"Molecules"},{"issue":"9","key":"12445_CR62","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1016\/j.chembiol.2019.06.005","volume":"26","author":"ES Reckzeh","year":"2019","unstructured":"Reckzeh ES, Karageorgis G, Schwalfenberg M, Ceballos J, Nowacki J, Stroet MCM et al (2019) Inhibition of glucose transporters and glutaminase synergistically impairs tumor cell growth. Cell Chem Biol 26(9):1214-1228.e25. https:\/\/doi.org\/10.1016\/j.chembiol.2019.06.005","journal-title":"Cell Chem Biol"},{"issue":"19","key":"12445_CR63","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14194568","volume":"14","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Li Q, Huang Z, Li B, Nice EC, Huang C et al (2022) Targeting glucose metabolism enzymes in cancer treatment: current and emerging strategies. Cancers (Basel) 14(19):4568. https:\/\/doi.org\/10.3390\/cancers14194568","journal-title":"Cancers (Basel)"},{"key":"12445_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.114585","volume":"162","author":"Y Hu","year":"2023","unstructured":"Hu Y, Yang L, Lai Y (2023) Recent findings regarding the synergistic effects of emodin and its analogs with other bioactive compounds: Insights into new mechanisms. Biomed Pharmacother. 162:114585. https:\/\/doi.org\/10.1016\/j.biopha.2023.114585","journal-title":"Biomed Pharmacother."},{"issue":"6","key":"12445_CR65","doi-asserted-by":"publisher","first-page":"3015","DOI":"10.3892\/or.2015.3914","volume":"33","author":"H Zhang","year":"2015","unstructured":"Zhang H, Chen L, Bu HQ, Yu QJ, Jiang DD, Pan FP et al (2015) Effects of emodin on the demethylation of tumor-suppressor genes in pancreatic cancer PANC-1 cells. Oncol Rep 33(6):3015\u201323. https:\/\/doi.org\/10.3892\/or.2015.3914","journal-title":"Oncol Rep"},{"issue":"3","key":"12445_CR66","doi-asserted-by":"publisher","first-page":"3943","DOI":"10.1096\/fj.201901237R","volume":"34","author":"SH Jiang","year":"2020","unstructured":"Jiang SH, Dong FY, Da LT, Yang XM, Wang XX, Weng JY et al (2020) Ikarugamycin inhibits pancreatic cancer cell glycolysis by targeting hexokinase 2. FASEB J 34(3):3943\u20133955. https:\/\/doi.org\/10.1096\/fj.201901237R","journal-title":"FASEB J"},{"issue":"1","key":"12445_CR67","doi-asserted-by":"publisher","DOI":"10.1186\/s40170-021-00248-7","volume":"9","author":"P Shriwas","year":"2021","unstructured":"Shriwas P, Roberts D, Li Y, Wang L, Qian Y, Bergmeier S et al (2021) A small-molecule pan-class I glucose transporter inhibitor reduces cancer cell proliferation in vitro and tumor growth in vivo by targeting glucose-based metabolism. Cancer Metab 9(1):14. https:\/\/doi.org\/10.1186\/s40170-021-00248-7","journal-title":"Cancer Metab"},{"issue":"8","key":"12445_CR68","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1158\/1535-7163.MCT-13-0097","volume":"12","author":"BF Clem","year":"2013","unstructured":"Clem BF, O\u2019Neal J, Tapolsky G, Clem AL, Imbert-Fernandez Y, Kerr DA 2nd et al (2013) Targeting 6-phosphofructo-2-kinase (PFKFB3) as a therapeutic strategy against cancer. Mol Cancer Ther 12(8):1461\u201370. https:\/\/doi.org\/10.1158\/1535-7163.MCT-13-0097","journal-title":"Mol Cancer Ther"},{"issue":"6","key":"12445_CR69","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26061642","volume":"26","author":"C Curcio","year":"2021","unstructured":"Curcio C, Brugiapaglia S, Bulfamante S, Follia L, Cappello P, Novelli F (2021) The glycolytic pathway as a target for novel onco-immunology therapies in pancreatic cancer. Molecules 26(6):1642. https:\/\/doi.org\/10.3390\/molecules26061642","journal-title":"Molecules"},{"issue":"9","key":"12445_CR70","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11091372","volume":"11","author":"GH Mohammad","year":"2019","unstructured":"Mohammad GH, Vassileva V, Acedo P, Olde Damink SWM, Malago M, Dhar DK et al (2019) Targeting pyruvate kinase M2 and lactate dehydrogenase A is an effective combination strategy for the treatment of pancreatic cancer. Cancers (Basel) 11(9):1372. https:\/\/doi.org\/10.3390\/cancers11091372","journal-title":"Cancers (Basel)"},{"issue":"8","key":"12445_CR71","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1007\/s13238-014-0082-8","volume":"5","author":"P Jiang","year":"2014","unstructured":"Jiang P, Du W, Wu M (2014) Regulation of the pentose phosphate pathway in cancer. Protein Cell 5(8):592\u2013602. https:\/\/doi.org\/10.1007\/s13238-014-0082-8","journal-title":"Protein Cell"},{"issue":"3","key":"12445_CR72","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1038\/ncb2172","volume":"13","author":"P Jiang","year":"2011","unstructured":"Jiang P, Du W, Wang X, Mancuso A, Gao X, Wu M et al (2011) P53 regulates biosynthesis through direct inactivation of glucose-6-phosphate dehydrogenase. Nat Cell Biol 13(3):310\u20136. https:\/\/doi.org\/10.1038\/ncb2172","journal-title":"Nat Cell Biol"},{"issue":"10","key":"12445_CR73","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1038\/s41401-020-00588-y","volume":"42","author":"J Tang","year":"2021","unstructured":"Tang J, Chen L, Qin ZH, Sheng R (2021) Structure, regulation, and biological functions of TIGAR and its role in diseases. Acta Pharmacol Sin 42(10):1547\u20131555. https:\/\/doi.org\/10.1038\/s41401-020-00588-y","journal-title":"Acta Pharmacol Sin"},{"issue":"3","key":"12445_CR74","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.bj.2020.08.001","volume":"44","author":"HC Yang","year":"2021","unstructured":"Yang HC, Stern A, Chiu DT (2021) G6PD: a hub for metabolic reprogramming and redox signaling in cancer. Biomed J 44(3):285\u2013292. https:\/\/doi.org\/10.1016\/j.bj.2020.08.001","journal-title":"Biomed J"},{"issue":"2","key":"12445_CR75","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41568-019-0216-7","volume":"20","author":"G Hoxhaj","year":"2020","unstructured":"Hoxhaj G, Manning BD (2020) The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism. Nat Rev Cancer. 20(2):74\u201388. https:\/\/doi.org\/10.1038\/s41568-019-0216-7","journal-title":"Nat Rev Cancer."},{"issue":"24","key":"12445_CR76","doi-asserted-by":"publisher","first-page":"36719","DOI":"10.18632\/oncotarget.9165","volume":"7","author":"YS Wu","year":"2016","unstructured":"Wu YS, Looi CY, Subramaniam KS, Masamune A, Chung I (2016) Soluble factors from stellate cells induce pancreatic cancer cell proliferation via Nrf2-activated metabolic reprogramming and ROS detoxification. Oncotarget 7(24):36719\u201336732. https:\/\/doi.org\/10.18632\/oncotarget.9165","journal-title":"Oncotarget"},{"key":"12445_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113607","volume":"154","author":"S Hao","year":"2022","unstructured":"Hao S, Meng Q, Sun H, Li Y, Li Y, Gu L et al (2022) The role of transketolase in human cancer progression and therapy. Biomed Pharmacother 154:113607. https:\/\/doi.org\/10.1016\/j.biopha.2022.113607","journal-title":"Biomed Pharmacother"},{"issue":"2","key":"12445_CR78","doi-asserted-by":"publisher","DOI":"10.3390\/life12020271","volume":"12","author":"J Song","year":"2022","unstructured":"Song J, Sun H, Zhang S, Shan C (2022) The multiple roles of glucose-6-phosphate dehydrogenase in tumorigenesis and cancer chemoresistance. Life (Basel) 12(2):271. https:\/\/doi.org\/10.3390\/life12020271","journal-title":"Life (Basel)"},{"issue":"16","key":"12445_CR79","doi-asserted-by":"publisher","first-page":"4549","DOI":"10.1158\/0008-5472.CAN-17-4047","volume":"78","author":"S Wu","year":"2018","unstructured":"Wu S, Wang H, Li Y, Xie Y, Huang C, Zhao H et al (2018) Transcription factor YY1 promotes cell proliferation by directly activating the pentose phosphate pathway. Cancer Res 78(16):4549\u20134562. https:\/\/doi.org\/10.1158\/0008-5472.CAN-17-4047","journal-title":"Cancer Res"},{"issue":"4","key":"12445_CR80","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.molcel.2014.06.020","volume":"55","author":"C Shan","year":"2014","unstructured":"Shan C, Elf S, Ji Q, Kang HB, Zhou L, Hitosugi T et al (2014) Lysine acetylation activates 6-phosphogluconate dehydrogenase to promote tumor growth. Mol Cell 55(4):552\u201365. https:\/\/doi.org\/10.1016\/j.molcel.2014.06.020","journal-title":"Mol Cell"},{"issue":"9","key":"12445_CR81","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1016\/j.bbapap.2014.06.003","volume":"1844","author":"GA Kochetov","year":"2014","unstructured":"Kochetov GA, Solovjeva ON (2014) Structure and functioning mechanism of transketolase. Biochim Biophys Acta 1844(9):1608\u201318. https:\/\/doi.org\/10.1016\/j.bbapap.2014.06.003","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"12445_CR82","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-019-1131-1","volume":"38","author":"Z Qin","year":"2019","unstructured":"Qin Z, Xiang C, Zhong F, Liu Y, Dong Q, Li K et al (2019) Transketolase (TKT) activity and nuclear localization promote hepatocellular carcinoma in a metabolic and a non-metabolic manner. J Exp Clin Cancer Res 38(1):154. https:\/\/doi.org\/10.1186\/s13046-019-1131-1","journal-title":"J Exp Clin Cancer Res"},{"issue":"8","key":"12445_CR83","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1002\/jgh3.12604","volume":"5","author":"HR Fazli","year":"2021","unstructured":"Fazli HR, Mohamadkhani A, Godarzi HR, Pourshams A, Jafari Nia M (2021) Dehydroepiandrosterone modulates oxidative DNA damage in pancreatic cancer: a case-control study. JGH Open 5(8):902\u2013906. https:\/\/doi.org\/10.1002\/jgh3.12604","journal-title":"JGH Open"},{"key":"12445_CR84","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.biopha.2016.11.078","volume":"85","author":"Y Dong","year":"2017","unstructured":"Dong Y, Wang M (2017) Knockdown of TKTL1 additively complements cisplatin-induced cytotoxicity in nasopharyngeal carcinoma cells by regulating the levels of NADPH and ribose-5-phosphate. Biomed Pharmacother 85:672\u2013678. https:\/\/doi.org\/10.1016\/j.biopha.2016.11.078","journal-title":"Biomed Pharmacother"},{"key":"12445_CR85","doi-asserted-by":"publisher","DOI":"10.1186\/2162-3619-2-18","volume":"2","author":"J Wang","year":"2013","unstructured":"Wang J, Zhang X, Ma D, Lee WP, Xiao J, Zhao Y, Go VL, Wang Q, Yen Y, Recker R, Xiao GG (2013) Inhibition of transketolase by oxythiamine altered dynamics of protein signals in pancreatic cancer cells. Exp Hematol Oncol 2:18. https:\/\/doi.org\/10.1186\/2162-3619-2-18","journal-title":"Exp Hematol Oncol"},{"key":"12445_CR86","doi-asserted-by":"publisher","unstructured":"Liberti MV, Locasale JW. (2016) The warburg effect: how does it benefit cancer cells? Trends Biochem Sci. 2016 Mar;41(3):211-218. https:\/\/doi.org\/10.1016\/j.tibs.2015.12.001. Erratum in: Trends Biochem Sci. 2016 Mar;41(3):287. Erratum in: Trends Biochem Sci. 2016 ;41(3):287. 10.1016\/j.tibs.2016.01.004.","DOI":"10.1016\/j.tibs.2015.12.001"},{"key":"12445_CR87","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/3966386","author":"J Xu","year":"2022","unstructured":"Xu J, Li Y, Li Z, Shao W, Song J, Wei J (2022) Acidic tumor microenvironment promotes pancreatic cancer through miR-451a\/MEF2D axis. J Oncol. https:\/\/doi.org\/10.1155\/2022\/3966386","journal-title":"J Oncol"},{"key":"12445_CR88","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.759376","volume":"11","author":"Y Li","year":"2021","unstructured":"Li Y, Zhang J, Xu J, Liu S (2021) The metabolism symbiosis between pancreatic cancer and tumor microenvironment. Front Oncol 11:759376. https:\/\/doi.org\/10.3389\/fonc.2021.759376","journal-title":"Front Oncol"},{"issue":"16","key":"12445_CR89","doi-asserted-by":"publisher","first-page":"R921","DOI":"10.1016\/j.cub.2020.06.081","volume":"30","author":"NM Anderson","year":"2020","unstructured":"Anderson NM, Simon MC (2020) The tumor microenvironment. Curr Biol 30(16):R921\u2013R925. https:\/\/doi.org\/10.1016\/j.cub.2020.06.081","journal-title":"Curr Biol"},{"issue":"9","key":"12445_CR90","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.107701","volume":"31","author":"LM Becker","year":"2020","unstructured":"Becker LM, O\u2019Connell JT, Vo AP, Cain MP, Tampe D, Bizarro L et al (2020) Fibroblasts deregulates glucose metabolism and facilitates progression of breast cancer. Cell Rep. 31(9):107701. https:\/\/doi.org\/10.1016\/j.celrep.2020.107701","journal-title":"Cell Rep."},{"issue":"13","key":"12445_CR91","doi-asserted-by":"publisher","first-page":"1038650","DOI":"10.3389\/fimmu.2022.1038650","volume":"12","author":"S Dong","year":"2022","unstructured":"Dong S, Li W, Li X, Wang Z, Chen Z, Shi H et al (2022) Glucose metabolism and tumour microenvironment in pancreatic cancer: a key link in cancer progression. Front Immunol. 12(13):1038650. https:\/\/doi.org\/10.3389\/fimmu.2022.1038650","journal-title":"Front Immunol."},{"issue":"20","key":"12445_CR92","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202415196","volume":"12","author":"M Tao","year":"2025","unstructured":"Tao M, Liu W, Chen J, Liu R, Zou J, Yu B et al (2025) Transcriptome landscape of cancer\u2010associated fibroblasts in human PDAC. Adv Sci 12(20):2415196.b. https:\/\/doi.org\/10.1002\/advs.202415196","journal-title":"Adv Sci"},{"issue":"12","key":"12445_CR93","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1158\/0008-5472.CAN-24-3173","volume":"85","author":"T Li","year":"2025","unstructured":"Li T, Hu C, Huang T, Zhou Y, Tian Q, Chen H et al (2025) Cancer-associated fibroblasts foster a high-lactate microenvironment to drive perineural invasion in pancreatic cancer. Cancer Res 85(12):2199\u2013217. https:\/\/doi.org\/10.1158\/0008-5472.CAN-24-3173","journal-title":"Cancer Res"},{"issue":"1","key":"12445_CR94","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1186\/s12967-025-07164-0","volume":"23","author":"Q Zhang","year":"2025","unstructured":"Zhang Q, Cao Z, Yan S, Chen B, Wu H, Cao H et al (2025) Metabolic and immune crosstalk between cancer-associated fibroblasts and pancreatic cancer cells. J Trans Med. 23(1):1118. https:\/\/doi.org\/10.1186\/s12967-025-07164-0","journal-title":"J Trans Med."},{"issue":"1","key":"12445_CR95","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01860-5","volume":"22","author":"H Zhang","year":"2023","unstructured":"Zhang H, Yue X, Chen Z, Liu C, Wu W, Zhang N et al (2023) Define cancer-associated fibroblasts (CAFs) in the tumor microenvironment: new opportunities in cancer immunotherapy and advances in clinical trials. Mol Cancer 22(1):159. https:\/\/doi.org\/10.1186\/s12943-023-01860-5","journal-title":"Mol Cancer"},{"issue":"24","key":"12445_CR96","doi-asserted-by":"publisher","first-page":"4979","DOI":"10.1002\/cam4.4830","volume":"11","author":"Y Pan","year":"2022","unstructured":"Pan Y, Tang H, Li Q, Chen G, Li D (2022) Exosomes and their roles in the chemoresistance of pancreatic cancer. Cancer Med 11(24):4979\u201388. https:\/\/doi.org\/10.1002\/cam4.4830","journal-title":"Cancer Med"},{"issue":"11","key":"12445_CR97","doi-asserted-by":"publisher","first-page":"2616","DOI":"10.1002\/ijc.29324","volume":"136","author":"B Madhavan","year":"2015","unstructured":"Madhavan B, Yue S, Galli U, Rana S, Gross W, M\u00fcller M et al (2015) Combined evaluation of a panel of protein and miRNA serum\u2010exosome biomarkers for pancreatic cancer diagnosis increases sensitivity and specificity. Int J Cancer 136(11):2616\u201327. https:\/\/doi.org\/10.1002\/ijc.29324","journal-title":"Int J Cancer"},{"issue":"1","key":"12445_CR98","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-01245-y","volume":"19","author":"AN Ariston Gabriel","year":"2020","unstructured":"Ariston Gabriel AN, Wang F, Jiao Q, Yvette U, Yang X, Al-Ameri SA et al (2020) The involvement of exosomes in the diagnosis and treatment of pancreatic cancer. Mol Cancer 19(1):132. https:\/\/doi.org\/10.1186\/s12943-020-01245-y","journal-title":"Mol Cancer"},{"issue":"4","key":"12445_CR99","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.541","volume":"5","author":"Y Wu","year":"2024","unstructured":"Wu Y, Han W, Dong H, Liu X, Su X (2024) The rising roles of exosomes in the tumor microenvironment reprogramming and cancer immunotherapy. MedComm 5(4):e541. https:\/\/doi.org\/10.1002\/mco2.541","journal-title":"MedComm"},{"issue":"23","key":"12445_CR100","doi-asserted-by":"publisher","first-page":"5058","DOI":"10.1158\/0008-5472.CAN-15-0744","volume":"75","author":"M Wang","year":"2015","unstructured":"Wang M, Topalovski M, Toombs JE, Wright CM, Moore ZR, Boothman DA et al (2015) Fibulin-5 blocks microenvironmental ROS in pancreatic cancer. Cancer Res 75(23):5058\u201369. https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-0744","journal-title":"Cancer Res"},{"issue":"2","key":"12445_CR101","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/ncb3094","volume":"17","author":"MY Fong","year":"2015","unstructured":"Fong MY, Zhou W, Liu L, Alontaga AY, Chandra M, Ashby J et al (2015) Breast-cancer-secreted miR-122 reprograms glucose metabolism in premetastatic niche to promote metastasis. Nat Cell Biol 17(2):183\u201394. https:\/\/doi.org\/10.1038\/ncb3094","journal-title":"Nat Cell Biol"},{"issue":"7519","key":"12445_CR102","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/nature13490","volume":"513","author":"OR Colegio","year":"2014","unstructured":"Colegio OR, Chu NQ, Szabo AL, Chu T, Rhebergen AM, Jairam V et al (2014) Functional polarization of tumor-associated macrophages by tumor-derived lactic acid. Nature. 513(7519):559\u201363. https:\/\/doi.org\/10.1038\/nature13490","journal-title":"Nature."},{"issue":"5","key":"12445_CR103","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1038\/s41577-019-0140-9","volume":"19","author":"D O\u2019Sullivan","year":"2019","unstructured":"O\u2019Sullivan D, Sanin DE, Pearce EJ, Pearce EL (2019) Metabolic interventions in the immune response to cancer. Nat Rev Immunol. 19(5):324\u2013335. https:\/\/doi.org\/10.1038\/s41577-019-0140-9","journal-title":"Nat Rev Immunol."},{"issue":"11","key":"12445_CR104","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","volume":"20","author":"AD Waldman","year":"2020","unstructured":"Waldman AD, Fritz JM, Lenardo MJ (2020) A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol. 20(11):651\u2013668. https:\/\/doi.org\/10.1038\/s41577-020-0306-5","journal-title":"Nat Rev Immunol."}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12445-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-12445-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12445-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T10:28:38Z","timestamp":1785493718000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-12445-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,31]]},"references-count":104,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["12445"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-12445-y","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,31]]},"assertion":[{"value":"7 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is a narrative review based on previously published literature and does not involve any studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the authors have consented to participate.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the authors have consented to the publication of the text.","order":4,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1315"}}